Back to Search
MICHAEL MORRIS, MD
MD
Medical Oncology Physician
NPI: 1255302055IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
202032(NY)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Class of 1994
Research & Publications (20)
Features of nephrogenic systemic fibrosis on radiology examinations.
PMID 19542396·AJR Am J Roentgenol·2009
6-review
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.
PMID 19375217·Eur Urol·2009
3-trial
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
PMID 19364960·J Clin Oncol·2009
3-trial
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
PMID 19213669·Clin Genitourin Cancer·2009
8-other
Mistaken identity: activating conservative political identities induces "conservative" financial decisions.
PMID 19076488·Psychol Sci·2008
8-other
Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid.
PMID 18523892·AAPS J·2008
6-review
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
PMID 17936848·J Urol·2007
3-trial
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
PMID 17473203·Clin Cancer Res·2007
3-trial
Randomized, controlled trials as minimal risk: an ethical analysis.
PMID 17255879·Crit Care Med·2007
8-other
Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study.
PMID 17019430·Nat Clin Pract Oncol·2006
8-other
A paradigm for inpatient resuscitation research with an exception from informed consent.
PMID 16915111·Crit Care Med·2006
8-other
An ethical analysis of exception from informed consent regulations.
PMID 16264082·Acad Emerg Med·2005
8-other
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
PMID 16243819·Clin Cancer Res·2005
3-trial
Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.
PMID 15869719·Curr Urol Rep·2005
6-review
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.
PMID 15867215·Clin Cancer Res·2005
4-observational
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.
PMID 15722787·Appl Immunohistochem Mol Morphol·2005
3-trial
Renal clearance of gamma-hydroxybutyric acid in rats: increasing renal elimination as a detoxification strategy.
PMID 15722403·J Pharmacol Exp Ther·2005
7-preclinical
Survival outcomes after extracorporeal cardiopulmonary resuscitation instituted during active chest compressions following refractory in-hospital pediatric cardiac arrest.
PMID 15329159·Pediatr Crit Care Med·2004
4-observational
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
PMID 15112267·Cancer·2004
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (212) 639-2000
Quick Facts
- NPI
- 1255302055
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile